Effects of Dopamine D1- or D2-like Receptor Antagonists on the Hypermotive and Discriminative Stimulus Effects of (+)-MDMA
Overview
Affiliations
Rationale: Both dopamine (DA) and serotonin (5-HT) release are evoked by (+)-MDMA; however, little is known of the contribution of DA D1- and D2-like receptors (D1R and D2R, respectively) in the behavioral effects of (+)-MDMA. OBJECTIVES. To test the hypothesis that a D1R or D2R antagonist would attenuate the hypermotive or discriminative stimulus effects of (+)-MDMA.
Methods: Male Sprague-Dawley rats (n=164) were pretreated with the D1R antagonist SCH 23390 (3.125-50 microg/kg, s.c.) or the D2R antagonist eticlopride (12.5-50 microg/kg, s.c.) prior to treatment with (+)-MDMA (3 mg/kg, s.c.) and locomotor activity was recorded using photobeam monitors. Twelve additional rats trained to discriminate (+)-MDMA (1 mg/kg, i.p.) from saline in a two-lever water-reinforced FR20 task were administered SCH 23390 (6.25 microg/kg, i.p.) or eticlopride (12.5 microg/kg, i.p.) prior to (+)-MDMA (0.375-1.0 mg/kg, i.p.). Rats were then placed in the drug discrimination chambers and the percent (+)-MDMA appropriate responding and response rate were measured.
Results: Both SCH 23390 and eticlopride blocked (+)-MDMA-evoked hyperactivity in a dose-related manner; the highest doses of the antagonists also effectively suppressed basal locomotor activity. In rats trained to discriminate (+)-MDMA from saline, SCH 23390 (6.25 microg/kg), but not eticlopride (12.5 microg/kg), blocked the stimulus effects of (+)-MDMA without altering response rate. CONCLUSION. These data indicate that DA released indirectly by (+)-MDMA administration results in stimulation of D1R and D2R to enhance locomotor activity. Furthermore, the D1R appears to play a more prominent role than the D2R in the discriminative stimulus properties of (+)-MDMA.
van de Wetering R, Vorster J, Geyrhofer S, Harvey J, Keyzers R, Schenk S Metabolomics. 2023; 19(8):69.
PMID: 37530897 PMC: 10397151. DOI: 10.1007/s11306-023-02034-6.
van de Wetering R, Schenk S Psychopharmacology (Berl). 2017; 234(7):1155-1164.
PMID: 28188355 DOI: 10.1007/s00213-017-4554-4.
Shin E, Dang D, Tran H, Nam Y, Jeong J, Lee Y Neurochem Int. 2016; 100:146-158.
PMID: 27623093 PMC: 7066575. DOI: 10.1016/j.neuint.2016.09.008.
Lizarraga L, Cholanians A, Phan A, Herndon J, Lau S, Monks T Toxicol Sci. 2014; 143(1):209-19.
PMID: 25370842 PMC: 4274386. DOI: 10.1093/toxsci/kfu222.
Saez-Briones P, Hernandez A Curr Neuropharmacol. 2014; 11(5):521-34.
PMID: 24403876 PMC: 3763760. DOI: 10.2174/1570159X11311050007.